Equity Profile

NVO

Novo Nordisk A/S

Health CarePharmaceuticals$217.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Novo Nordisk A/S is a leading global healthcare company focused on diabetes care and hormone replacement therapies. With a market cap of $218 billion, it plays a crucial role in the pharmaceutical industry, particularly as demand for diabetes treatments continues to grow amid rising global health concerns.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and growth potential, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, particularly in the diabetes segment.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

NVO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+37.68%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q1 2026, Novo Nordisk reported an EPS of $1.04, exceeding expectations by 18.71%. The stock reacted positively, gaining nearly 2% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are eager to see if Novo Nordisk can maintain its growth trajectory in the competitive diabetes market. The upcoming earnings report will be crucial in assessing the company's performance.

Bull Case

If Novo Nordisk continues to outperform expectations, particularly in EPS and revenue growth, it could solidify its position as a market leader and attract more investment.

Bear Case

Conversely, if the company fails to meet earnings expectations or shows signs of slowing growth, it could lead to a decline in investor confidence and a drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability, and a significant deviation from expectations could impact stock performance.

How is revenue growth tracking in the diabetes segment?

Given the competitive landscape, insights into revenue growth will be vital for assessing the company's market position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Novo Nordisk's ability to capitalize on the growing diabetes market, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Recent positive EPS surprises indicate a trend of exceeding expectations.

The company's strong market position in diabetes care suggests resilience against competition.

Key Risk

If revenue growth in the diabetes segment exceeds expectations, it could significantly alter market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching how Novo Nordisk performs against expectations, especially in light of recent earnings surprises.

Bull Confirmed If

An EPS of $1.10 or higher would confirm strong growth and investor confidence.

Bear Confirmed If

An EPS below $0.90 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±9.26%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±9.3% while NVO has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.8%

Calls (2.8M)P/C Ratio: 0.57Puts (1.1M)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

9.45%

of float

Insider

0.01%

of float

Holders

1,641

institutions

Top Holders· as of Dec 2025

LOOMIS SAYLES & CO L P
17,135,384 sh · $705.5M
0.51%
6.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novo Nordisk beats expectations, history suggests a potential stock increase of around 3% on the first day, confirming strong growth.

In-Line / Cautious

If results are in line with expectations, the stock may experience moderate movement as investors digest the news.

Miss

A miss could lead to a decline of about 4% based on historical patterns, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new diabetes treatment approvals.
2Insights into market share changes in the diabetes segment.
3Management's outlook on future revenue growth.
4Details on cost management and operational efficiency.
5Responses to competitive pressures in the pharmaceutical market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and growth potential, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, particularly in the diabetes segment.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

NVO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+37.68%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q1 2026, Novo Nordisk reported an EPS of $1.04, exceeding expectations by 18.71%. The stock reacted positively, gaining nearly 2% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are eager to see if Novo Nordisk can maintain its growth trajectory in the competitive diabetes market. The upcoming earnings report will be crucial in assessing the company's performance.

Bull Case

If Novo Nordisk continues to outperform expectations, particularly in EPS and revenue growth, it could solidify its position as a market leader and attract more investment.

Bear Case

Conversely, if the company fails to meet earnings expectations or shows signs of slowing growth, it could lead to a decline in investor confidence and a drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability, and a significant deviation from expectations could impact stock performance.

How is revenue growth tracking in the diabetes segment?

Given the competitive landscape, insights into revenue growth will be vital for assessing the company's market position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Novo Nordisk's ability to capitalize on the growing diabetes market, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Recent positive EPS surprises indicate a trend of exceeding expectations.

The company's strong market position in diabetes care suggests resilience against competition.

Key Risk

If revenue growth in the diabetes segment exceeds expectations, it could significantly alter market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching how Novo Nordisk performs against expectations, especially in light of recent earnings surprises.

Bull Confirmed If

An EPS of $1.10 or higher would confirm strong growth and investor confidence.

Bear Confirmed If

An EPS below $0.90 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±9.26%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±9.3% while NVO has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.8%

Calls (2.8M)P/C Ratio: 0.57Puts (1.1M)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

9.45%

of float

Insider

0.01%

of float

Holders

1,641

institutions

Top Holders· as of Dec 2025

LOOMIS SAYLES & CO L P
17,135,384 sh · $705.5M
0.51%
6.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novo Nordisk beats expectations, history suggests a potential stock increase of around 3% on the first day, confirming strong growth.

In-Line / Cautious

If results are in line with expectations, the stock may experience moderate movement as investors digest the news.

Miss

A miss could lead to a decline of about 4% based on historical patterns, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new diabetes treatment approvals.
2Insights into market share changes in the diabetes segment.
3Management's outlook on future revenue growth.
4Details on cost management and operational efficiency.
5Responses to competitive pressures in the pharmaceutical market.